Search Results
Oct 28, 2025, 06:50 ET Labcorp Announces 2025 Third Quarter Results
European Union's In Vitro Diagnostic Regulation.Geneoscopy received FDA approval for a simplified at-home collection method for ColoSense®, its RNA-based colorectal cancer screening test that Labcorp will make available to patients and providers.The company expanded access to its Invitae
More news about: Labcorp Holdings Inc
Oct 28, 2025, 06:30 ET Bio-Techne Launches ProximityScope™ Assay on the BOND RX platform from Leica Biosystems to Advance Spatial Protein-Protein Interactions Research
interactions directly within fixed tissue at subcellular resolution Enables simultaneous detection of protein proximity, RNA, and proteins on the same tissue section Automates spatial multiomic workflows with the BOND RX platform from Leica Biosystems
More news about: Bio-Techne Corporation
Oct 27, 2025, 17:30 ET $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Avidity Biosciences, Inc. (NASDAQ: RNA)
RNA) related to its sale to Novartis AG. Under the terms of the proposed transaction, Avidity shareholders will receive $72.00 per share in cash.
More news about: Monteverde & Associates PC
Oct 27, 2025, 17:02 ET Autocuidado masculino: homens recorrem a procedimentos estéticos para realçar a beleza e cuidar da pele
2014;20(2):97-103 23. Waibel J, Ziegler M, Nguyen TQ, Le JHTD, Qureshi A, Widgerow A, Meckfessel M. Comparative Bulk RNA-Seq Analysis of Poly-l-Lactic Acid Versus Calcium Hydroxylapatite Reveals a Novel, Adipocyte-Mediated Regenerative Mechanism of Action Unique to PLLA.
More news about: Galderma
Oct 27, 2025, 13:01 ET HALPER SADEH LLC ENCOURAGES ADVM, PLYM, RNA SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
multimedia:https://www.prnewswire.com/news-releases/halper-sadeh-llc-encourages-advm-plym-rna-shareholders-to-contact-the-firm-to-discuss-their-rights-302595545.html
More news about: Halper Sadeh LLP
Oct 27, 2025, 08:45 ET Co-Diagnostics Signs Definitive Agreement with Arabian Eagle in the Kingdom of Saudi Arabia to Establish CoMira Diagnostics and Localize Co-Dx™ PCR Platform Across the Middle East
diagnostics technologies. The Company's technologies are utilized for tests that are designed to detect and/or analyze nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics
Oct 27, 2025, 08:30 ET Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology
oncology, nanocarrier delivery has accelerated following regulatory validations such as FDA approvals of nanoparticle-formulated chemotherapies and RNA therapies. These new formulations are not simply incremental improvements; they can transform once-marginal drugs into category-changing assets. As precision
More news about: NetworkNewsWire
Oct 27, 2025, 08:00 ET Pancreatic Cancer Clinical Trial Data for Diakonos Oncology's DOC1021 Cell-Based Immunotherapy to be Presented at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
which mimics a viral infection, unlocks a synergistic and exponentially more powerful tumor killing TH1 response driven by dual protein and RNA antigen sourcing, and it allows targeting of the complete cancer antigen pool. Moreover, the approach does not require any molecular modification of
More news about: Diakonos Oncology
Oct 26, 2025, 16:56 ET Ribo kriegt von der EMA den Status als Orphan Drug für das siRNA-Therapeutikum RBD1016 gegen Hepatitis-Delta-Virus-Infektion (HDV)
Dr. Li-Ming Gan, Co-Geschäftsführer und globaler Leiter der Forschungs- und Entwicklungsabteilung bei Ribo. „Das bestätigt unsere Strategie, mit innovativer RNA-Interferenz-Technologie schwere Krankheiten mit hohem ungedecktem Bedarf anzugehen. Wir treiben diese vielversprechende Therapie in der klinischen Entwicklung
More news about: Ribo Life Science
Oct 26, 2025, 13:07 ET Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG
Oct. 26, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates ("AOCs™") to profoundly improve people's lives, today announced
More news about: Avidity Biosciences, Inc.
Oct 24, 2025, 12:30 ET Whitehawk Therapeutics Presents Real-World Analysis Confirming PTK7 as a Broadly Expressed, Clinically Relevant Target Across Solid Tumors at AACR-NCI-EORTC
adult tissues and frequent overexpression in a wide range of cancers. There are no approved PTK7-directed ADCs. This large-scale RNA analysis of >157,000 tumor samples, nearly half from metastatic lesions, confirms PTK7 as one of the most broadly and highly expressed targets across
More news about: Whitehawk Therapeutics, Inc.
Oct 24, 2025, 12:14 ET Procedimentos estéticos injetáveis: quando é o momento certo para começar?
21. Waibel J, Ziegler M, Nguyen TQ, Le JHTD, Qureshi A, Widgerow A, Meckfessel M. Comparative Bulk RNA-Seq Analysis of Poly-l-Lactic Acid Versus Calcium Hydroxylapatite Reveals a Novel, Adipocyte-Mediated Regenerative Mechanism of Action Unique to PLLA.
More news about: Galderma
Oct 24, 2025, 08:00 ET Orna Therapeutics Announces Encore Presentation at the American College of Rheumatology Annual Meeting Supporting its in vivo CAR Therapy Approach in Autoimmune Diseases
TherapeuticsOrna Therapeutics is dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA®) therapeutics to unlock the potential of RNA medicine to treat diseases anywhere in the body. Orna's oRNA transcripts have advantages over traditional mRNA approaches,
More news about: Orna Therapeutics
Oct 24, 2025, 05:55 ET Ribo Granted EMA Orphan Drug Designation for siRNA Therapeutic RBD1016 for Hepatitis Delta Virus (HDV) Infection
Li-Ming Gan, Co-CEO and Global Head of R&D at Ribo. "It validates our strategy of targeting severe diseases with high unmet need through innovative RNA interference technology. We are advancing this promising therapy through clinical development, with the goal of delivering a new treatment to patients
More news about: Ribo Life Science
Oct 24, 2025, 05:43 ET Ribo Granted EMA Orphan Drug Designation for siRNA Therapeutic RBD1016 for Hepatitis Delta Virus (HDV) Infection
Li-Ming Gan, Co-CEO and Global Head of R&D at Ribo. "It validates our strategy of targeting severe diseases with high unmet need through innovative RNA interference technology. We are advancing this promising therapy through clinical development, with the goal of delivering a new treatment to patients
More news about: Ribo Life Science
Oct 23, 2025, 16:05 ET Insmed Ranks No. 1 on Science's 2025 Top Biopharma Employers List
early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout
More news about: Insmed Incorporated
Oct 23, 2025, 14:36 ET Zenocutuzumab-zbco Granted FDA Breakthrough Therapy Designation for NRG1+ Cholangiocarcinoma; Data Highlighting Potential of Zenocutuzumab-zbco in NRG1+ Cholangiocarcinoma to be Presented at AACR-NCI-EORTC
Cholangiocarcinoma Foundation. "The eNRGy trial results are encouraging, and they underscore how critical comprehensive molecular testing, notably tissue-based RNA NGS, is to ensure that patients with rare drivers such as NRG1 fusions are identified and can potentially have access to targeted treatments."
More news about: Partner Therapeutics, Inc.
Oct 23, 2025, 10:00 ET Pillar Biosciences to Showcase NGS Research Insights at 2025 AMP Meeting
Streamlined and Accurate Detection of Actionable Fusions with the oncoReveal® Multi-Cancer RNA Fusion v2 Panel (Poster Number: ST072) Saturday, November 15th
More news about: Pillar Biosciences, Inc.
Oct 23, 2025, 08:00 ET Ginkgo Bioworks in Partnership with STRM.BIO and University of British Columbia in Project to Develop In Vivo CAR Therapies Under ARPA-H's EMBODY Program
underscores Ginkgo's commitment to advancing RNA engineering and establishing itself as a credible partner in RNA cargo design for therapeutics companies. By participating in this groundbreaking program, Ginkgo plans to further develop and demonstrate its capabilities in RNA engineering and in vivo therapeutic
More news about: Ginkgo Bioworks
Oct 23, 2025, 08:00 ET Vial Initiates Phase 1 Trial of VIAL-INHBE, an INHBE (Activin E) siRNA for the Treatment of Obesity
including General Catalyst, Buckley Ventures, and Byers Capital. Vial is focused on advancing a pipeline of potentially best-in-class biologics and RNA therapeutics across areas of unmet medical need. Founded in 2020, Vial is a multidisciplinary team across R&D, Clinical Development, Clinical Operations,
More news about: Vial
Oct 22, 2025, 15:46 ET Pivot Bio CEO Chris Abbott Featured at the World Food Prize Foundation's 2025 Norman E. Borlaug International Dialogue
from nearly 400 applicants across 65 countries, these startups represent transformative, scalable ideas with the potential to reshape agriculture—from RNA-based crop protection to microbiome-powered soil solutions and AI-driven livestock care. The finalists will pitch their ventures
More news about: Pivot Bio, Inc
Oct 22, 2025, 12:00 ET Accent Therapeutics Presents New Preclinical Data on Lead Clinical Programs ATX-295 and ATX-559 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
About ATX-559 ATX-559 is a first-in-class potent and selective inhibitor of DHX9, a DNA/RNA helicase that plays a critical role in tumors with high levels of replication stress. Such tumors include those with BRCA loss of function (breast, ovarian),
More news about: Accent Therapeutics
Oct 22, 2025, 08:30 ET Co-Diagnostics Executive Leadership Team to Attend Global Health Exhibition 2025 in Riyadh, Saudi Arabia
diagnostics technologies. The Company's technologies are utilized for tests that are designed to detect and/or analyze nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics
Oct 22, 2025, 07:00 ET Basking Biosciences Doses First Patients in Part B of Phase 2 Stroke Trial, Unlocks $27.5 Million Financing Tranche, and Appoints Julia C. Owens, Ph.D. as Chief Executive Officer
RAISE trial of BB-031. BB-031 is an investigational RNA aptamer targeting von Willebrand Factor (vWF), a key mediator of clot formation and stabilization. By promoting clot dissolution and restoring blood
More news about: Basking Biosciences Inc.
Oct 20, 2025, 11:00 ET Plug and Play Lifetech Announces Inaugural Batch of 12 Innovative Startups in Indianapolis
biotech developing a disruptive RNA delivery platform technology, "OmniSomes." This proprietary technology is highly differentiated, utilizing bioengineered Mesenchymal Stem cell-derived extracellular vesicles (EVs) as novel non-viral vectors for highly efficient RNA delivery, which uniquely confers
More news about: Plug and Play